Stay updated on Dabrafenib/Trametinib in BRAF V600E+ Rare Cancers Clinical Trial
Sign up to get notified when there's something new on the Dabrafenib/Trametinib in BRAF V600E+ Rare Cancers Clinical Trial page.

Latest updates to the Dabrafenib/Trametinib in BRAF V600E+ Rare Cancers Clinical Trial page
- Check4 days agoChange DetectedLocations section updated with new sites in Arkansas, California, Maryland, Massachusetts, New York, Tennessee, Texas, Ontario, Baden-Wurttemberg, and Lombardy; corresponding regional 'Locations' entries were removed.SummaryDifference0.8%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedAdded a note indicating PubMed auto-filled publications. Updated the revision to v3.3.2; the old PubMed wording tied to v3.2.0 was removed.SummaryDifference0.1%

- Check41 days agoChange DetectedRemoved the funding-lapse notice that warned about possible delays in updates and operations. The page no longer displays guidance on government funding status or response times.SummaryDifference0.2%

- Check55 days agoChange DetectedThe changes appear to be cosmetic updates to formatting and minor textual tweaks; no core content like eligibility criteria, interventions, outcomes, or enrollment numbers was added or removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check84 days agoChange DetectedCore content updated with a new diagnosis term and new revision, plus an operating-status notice; a prior cancer term and old version are removed.SummaryDifference1%

- Check91 days agoChange DetectedTerminology updated from 'Plasma cell myeloma' to 'Multiple myeloma' and version bumped from v3.0.2 to v3.1.0.SummaryDifference0.1%

Stay in the know with updates to Dabrafenib/Trametinib in BRAF V600E+ Rare Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dabrafenib/Trametinib in BRAF V600E+ Rare Cancers Clinical Trial page.